Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Allakos Inc (ALLK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
05/14/2025: ALLK (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
Analysis of Past Performance
Type Stock | Historic Profit -85.27% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 05/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 29.74M USD | Price to earnings Ratio - | 1Y Target Price 0.3 |
Price to earnings Ratio - | 1Y Target Price 0.3 | ||
Volume (30-day avg) - | Beta 0.14 | 52 Weeks Range 0.22 - 1.55 | Updated Date 06/13/2025 |
52 Weeks Range 0.22 - 1.55 | Updated Date 06/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.78 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -52.64% | Return on Equity (TTM) -88.88% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -46918939 | Price to Sales(TTM) - |
Enterprise Value -46918939 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.5 | Shares Outstanding 90377000 | Shares Floating 57738232 |
Shares Outstanding 90377000 | Shares Floating 57738232 | ||
Percent Insiders 1.96 | Percent Institutions 76.72 |
Upturn AI SWOT
Allakos Inc
Company Overview
History and Background
Allakos Inc. is a biopharmaceutical company founded in 2012. It focused on developing antibodies targeting Siglec-8, an inhibitory receptor expressed on mast cells and eosinophils. The company aimed to treat allergic, inflammatory, and proliferative diseases. Following clinical trial failures, the company underwent significant restructuring.
Core Business Areas
- Drug Development: Focused on developing therapies for allergic and inflammatory diseases, primarily through the development of antibodies targeting Siglec-8.
Leadership and Structure
After restructuring, the leadership team consists of executives focused on streamlining operations and exploring strategic alternatives. The organizational structure is now lean, focusing on managing remaining assets and liabilities.
Top Products and Market Share
Key Offerings
- Lirentelimab (AK002): Lirentelimab was Allakos's lead product candidate, an antibody targeting Siglec-8. It was intended for eosinophilic gastrointestinal diseases (EGIDs) such as eosinophilic esophagitis (EoE). Clinical trials failed to meet primary endpoints, leading to the program's discontinuation. Competitors in the EGID space include Regeneron/Sanofi with Dupixent (dupilumab), although Dupixent is not specifically targeting Siglec-8.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and regulated, requiring significant investment in research and development, clinical trials, and regulatory approvals. The market for allergic and inflammatory disease treatments is substantial, with unmet needs driving innovation.
Positioning
Prior to the clinical trial failures, Allakos aimed to be a leader in Siglec-8 targeted therapies. The company no longer holds a significant position in the market due to the discontinued development of lirentelimab.
Total Addressable Market (TAM)
The TAM for EGIDs and other allergic and inflammatory diseases is estimated to be in the billions of dollars. Allakos's positioning relative to this TAM is currently minimal due to the cessation of clinical development programs.
Upturn SWOT Analysis
Strengths
Weaknesses
- Failed clinical trials
- Lack of current product pipeline
- Limited financial resources post-restructuring
- Damaged reputation
Opportunities
- Potential for out-licensing or sale of remaining assets
- New strategic direction or pivot
- Restructuring and cost reduction
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Lack of investor confidence
- Potential for further clinical trial failures if new programs are initiated
Competitors and Market Share
Key Competitors
- SNY
- REGN
Competitive Landscape
Allakos's competitive advantage was based on its Siglec-8 targeting approach. However, the failure of lirentelimab has significantly weakened its position compared to competitors with approved therapies.
Growth Trajectory and Initiatives
Historical Growth: Allakos experienced rapid growth in its early years, driven by its promising drug candidate. However, this growth halted after clinical trial failures.
Future Projections: Future projections are uncertain given the current state of the company. Any future growth is dependent on new strategic initiatives.
Recent Initiatives: Recent initiatives focus on cost reduction, exploring strategic alternatives, and managing existing assets.
Summary
Allakos is in a weak position following clinical trial failures and subsequent restructuring. Its promising drug candidate, lirentelimab, did not meet its primary endpoints, leading to the cessation of its development program. The company is currently focused on cost reduction and exploring strategic alternatives to manage its remaining assets. Investors should exercise caution due to the company's uncertain future and lack of a clear growth strategy.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry News Sources
Disclaimers:
This analysis is based on publicly available information and analyst estimates. It is not financial advice, and investors should conduct their own due diligence before making investment decisions. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Allakos Inc
Exchange NASDAQ | Headquaters San Carlos, CA, United States | ||
IPO Launch date 2018-07-19 | Chair of the Board, CEO & Director Dr. Robert Alexander Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.allakos.com |
Full time employees - | Website https://www.allakos.com | ||
As of May 15, 2025, operates as a subsidiary of Concentra Biosciences, LLC.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.